Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poorprognosis small cell lung cancer

Thorax

Volumn 64, Issue 1, 2009, Pages 75-80

  Lee, S M ^a   James, L E ^b   Qian, W ^c   Spiro, S ^a   Eisen, T ^d   Gower, N H ^b   Ferry, D R ^e   Gilligan, D ^f   Harper, P G ^g   Prendiville, J ^g   Hocking, M ^h   Rudd, R M ⁱ  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

ⁱ ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; GRANISETRON; METOCLOPRAMIDE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FEMALE; HAIR LOSS; HOSPITAL ADMISSION; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTPATIENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 58349115184     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2007.093872     Document Type: Article

References (25)

1. Sandler A. Chemotherapy for small-cell lung cancer. Semin Oncol 2003;30:9-25.
2. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-30.
3. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994;5:283-5.
4. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003;21:1550- 5.
5. Thatcher N, Lind M. Carboplatin small cell lung cancer. Semin Oncol 1990;17:40-8.
6. Skarlos DV, Samantas E, Kosmidis P, et al. Randomised comparison of etoposidecisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Co-operative Oncology Study Group. Ann Oncol 1994;5:601-7.
7. Lassen U, Kristjansen PE, Osterlind K, et al. Superiority of cisplatin and carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomised trial with 5 years fallow up. Ann Oncol 1996;7:365-71.
8. Souhami RL, Bradbury I, Geddes DM, et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985;45:2878-82.
9. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Stahel RA, Ginsberg R, Haddad R, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1993;5:119-26.
11. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997;89:577-80.
12. Cullen, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-98.
13. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication 48. Geneva: World Health Organization. 1979.
14. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionaires (QLQ-C30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-42.
15. Gower NH, Rudd RM, Ruiz de Elvira MC, et al. Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. Ann Oncol 1995;6:575-80.
16. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801.
17. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methology assessment and meta-analysis. Lung Cancer 2000;30:23-36.
18. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomised trials of a cisplatincontaining regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15.
19. Hesketh PJ, Batchelor D, Golant M, et al. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004;12:543-9.
20. Neubauer M, Heaven R, Olivares J, et al. Results of a phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer. Lung Cancer 2004;46:369-75.
21. Israel VP, Chansky K, Gandara D, et al. Southwest Oncology Group trial S9718 (2002): a phase II study of gemcitabine plus cisplatin in patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:1262.
22. De Marinis F, Nelli F, Lombardo M, et al: A multicenter, randomized, phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 2005;103:772-9.
23. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
24. Hanna NH, Bunn PA Jr, Langer C, et al. Randomised, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage small cell lung cancer. J Clin Oncol 2006;24:2038-43.
25. Sandler A, Langer C, Bunn PA, et al. Interim safety analysis of irinotecan and cisplatin combination chemotherapy for previously untreated extensive stage small cell lung cancer (abstract 2537). Proc Am Soc Clin Oncol 2003;22:631a.